JAK2

Editor’s note: This post has been edited from its original to reflect changes in 23andMe’s product. We’re posting a story about one of the participants in 23andMe’s MPN Research Initiative...

Take a moment to look back at the ten most interesting and significant genetic findings of 2012 or at least the ones that drew our attention. In the last 12...

Earlier this year we met our goal of enrolling 1,000 people in a community of people with a collection of rare blood disorders known as myeloproliferative neoplasms, or MPNs. Since...

Dr. Ross Levine Last year 23andMe launched a Myeloproliferative Neoplasms Research Initiative to study this group of rare blood cancers. We are now very close to reaching our goal of...

Myeloproliferative neoplasms (MPN) are a group of rare blood disorders. First characterized in 1951, it wasn't until 2005 that researchers began to uncover clues about the genetic basis of these diseases. An acquired mutation called V617F in the JAK2 gene is present in many people with MPN, and a growing body of research -- including evidence in 23andMe's MPN research cohort -- suggests that relatively common inherited genetic variants may predispose individuals to V617F-positive MPN.

Editor’s note: This post has been edited from its original to reflect changes in 23andMe’s product. Sometimes you can have too much of a good thing. Stem cells in your...